期刊
EUROPEAN JOURNAL OF HAEMATOLOGY
卷 86, 期 2, 页码 124-128出版社
WILEY
DOI: 10.1111/j.1600-0609.2010.01541.x
关键词
B-cell non-Hodgkin lymphoma; prognostic factors; gender; immunochemotherapy
类别
资金
- Finnish Academy of Sciences
- Finnish Cancer Societies
- Sigrid Juselius Foundation
- University of Helsinki
- Helsinki University Central Hospital
Male gender is an adverse prognostic factor in Hodgkin's lymphoma, but no such association has yet been established in non-Hodgkin lymphomas. Here, we have evaluated whether gender has prognostic impact on the survival of patients with B-cell non-Hodgkin lymphoma in the postrituximab era of lymphoma therapies. The study populations consisted of 217 diffuse large B-cell lymphoma (DLBCL) and 110 follicular lymphoma (FL) patients treated with immunochemotherapy. Hundred and sixty chemotherapy-treated DLBCL patients served as a control group. According to Kaplan-Meier analyses, female patients had a significantly better progression-free survival than men both in DLBCL (4 yr PFS 75% vs. 60%; P = 0.013) and in FL (4 yr PFS 68% vs. 52%, P = 0.036) patients treated with immunochemotherapy. In chemotherapy-treated DLBCL patients, no difference in survival between the genders was found. The results support the idea that women seem to respond better to rituximab.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据